Skip to main content
Quest Diagnostics

Sexual Health Laboratory Testing Considerations Among Transgender Patients

Sexual Health Laboratory Testing Considerations Among Transgender Patients

Authors: Starolis MW, Realegeno SE, Montero CI, Jones RS, Marlowe EM

Citation: Clin Microbiol Newsl. 2026 Jan 11. doi:10.1016/j.clinmicnews.2025.12.004. Online ahead of print.

Specialties: Infectious disease

Related content

Publication
Prevalence of Intersex/Differences in Sex Development and Primary Gonadal Insufficiency in a Pediatric Transgender Population
On-Demand Webinar
A Clinical View on Diagnostics Strategies for Sexually Transmitted Infections
Test FAQ
Chlamydia trachomatis Neisseria gonorrhoeae DNA SDA
Test FAQ
Chlamydia trachomatis Neisseria gonorrhoeae RNA TMA
Test FAQ
HIV Pre-exposure Prophylaxis (PrEP) Testing
Test FAQ
Mycoplasma genitalium
Publication
Insights into HIV-1 transmission dynamics using routinely collected data in the Mid-Atlantic United States
Test FAQ
HIV 1/2 Antigen and Antibodies Fourth Generation with Reflexes
Test FAQ
Syphilis (Treponema pallidum)

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.